Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 9/20 | 0.36 |
| ▸ | BCHE | P06276 | 7/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1327146 | 0.90 | C5AR1 (0.42) | C5AR1ACHEBCHEHTTSMN1; SMN2 | |
| SCHEMBL1329084 | 0.84 | C5AR1 (0.40) | C5AR1ACHEBCHEHTTSMN1; SMN2 | |
| SCHEMBL1327218 | 0.83 | BCHE (0.44) | C5AR1ACHEBCHEHTTSMN1; SMN2 | |
| SCHEMBL1327641 | 0.83 | C5AR1 (0.43) | C5AR1ACHEBCHEHTTSMN1; SMN2 | |
| SCHEMBL1328288 | 0.82 | C5AR1 (0.42) | C5AR1ACHEBCHEHTTSMN1; SMN2 | |
| SCHEMBL1326804 | 0.81 | C5AR1 (0.44) | C5AR1ACHEBCHEHTTSMN1; SMN2 | |
| SCHEMBL1328730 | 0.81 | ACHE (0.42) | C5AR1ACHEBCHEHTTSMN1; SMN2 | |
| SCHEMBL1327561 | 0.81 | C5AR1 (0.39) | C5AR1ACHEBCHEHTTSMN1; SMN2 | |
| SCHEMBL1327027 | 0.80 | C5AR1 (0.41) | C5AR1ACHEBCHEHTTSMN1; SMN2 | |
| SCHEMBL1330003 | 0.80 | ACHE (0.39) | C5AR1ACHEBCHEHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | claimed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885ACHE 2578/4885BCHE 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.